However, treatment of triple-negative breast cancer (TNBC) patients lack estrogen receptor (ER), progesteron receptor (PR) and human epidermal growth factor receptor 2 (HER2) has been challenging due to heterogeneity and devoid of well-defined molecular targets [6, 7]. Here, ERBB2 is linked to triple-negative breast carcinoma.